Your session is about to expire
← Back to Search
Tranexamic Acid (TXA) for Deep Vein Thrombosis (POISE-3 Trial)
POISE-3 Trial Summary
This trial is testing whether tranexamic acid can help prevent bleeding during surgery, and whether it's better to avoid low or high blood pressure during surgery.
- Deep Vein Thrombosis
- Perioperative Blood Loss
- Arterial Thrombosis
POISE-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPOISE-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.POISE-3 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the Food and Drug Administration (FDA) given its stamp of approval to Tranexamic Acid (TXA)?
"Tranexamic Acid (TXA) has received a 3 because it is in Phase 3 clinical trials. This suggests that while there is still some testing to be done, TXA has shown efficacy and multiple rounds of data support its safety."
Is this research project still enrolling new participants?
"This study is no longer recruiting patients. The trial was originally posted on June 27, 2018 and the last update occurred on January 24, 2022. There are other studies currently underway that might be of interest; as of right now, there are 164 trials actively enrolling participants with venous thrombosis and 68 trials for Tranexamic Acid (TXA) admitting new patients."
How is TXA most often used by doctors to help patients?
"TXA has shown to be an effective medication in the treatment of hyperfibrinolysis, hemophilia, and bleeding."
How does the TXA research compare to similar investigations?
"First studied in 2010 at the First Affiliated Hospital of Guangzhou TCM University, TXA has undergone 223 clinical trials. As of right now, 68 more are ongoing with a large chunk taking place in Edmonton, Alberta."
How many people are being chosen to participate in this clinical trial?
"This research is no longer actively recruiting patients. It was first posted on June 27th, 2018 and last updated January 24th, 2022. For those still seeking studies, there are 164 clinical trials for venous thrombosis and 68 for Tranexamic Acid (TXA) that are currently enrolling participants."
Why did researchers design this clinical trial?
"The primary outcome of this study is a composite of life-threatening bleeding, major bleeding, and critical organ bleeding. This will be measured over the course of roughly 30 days after randomization. Secondary outcomes include BIMS (defined as the number of patients who experience bleeding independently associated with mortality after noncardiac surgery), a net risk-benefit outcome (defined as a composite of vascular death, and non-fatal life-threatening,major or critical organ bleeding,MINS,stroke,peripheral arterial thrombosis,and symptomatic proximal venous thromboembolism), and MINS"
Share this study with friends
Copy Link
Messenger